Cytosorbents Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTSO research report →
Companywww.cytosorbents.com
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.
- CEO
- Phillip Chan
- IPO
- 2006
- Employees
- 149
- HQ
- Princeton, NJ, US
Price Chart
Valuation
- Market Cap
- $29.50M
- P/E
- -2.49
- P/S
- 0.79
- P/B
- 13.43
- EV/EBITDA
- -3.58
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 71.01%
- Op Margin
- -35.95%
- Net Margin
- -31.85%
- ROE
- -165.13%
- ROIC
- -41.10%
Growth & Income
- Revenue
- $37.06M · 4.13%
- Net Income
- $-8,198,000 · 60.43%
- EPS
- $-0.13 · 65.79%
- Op Income
- $-14,239,000
- FCF YoY
- 14.76%
Performance & Tape
- 52W High
- $1.39
- 52W Low
- $0.45
- 50D MA
- $0.62
- 200D MA
- $0.75
- Beta
- 1.44
- Avg Volume
- 86.76K
Get TickerSpark's AI analysis on CTSO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 25 | Chan Phillip P. | other | 100,000 |
| Aug 8, 25 | Chan Phillip P. | other | 105,600 |
| Aug 8, 25 | Chan Phillip P. | other | 136,400 |
| Aug 8, 25 | Jones Edward Raymond | other | 22,000 |
| Aug 8, 25 | BATOR MICHAEL G. | other | 44,000 |
| Aug 8, 25 | MARIANI PETER J | other | 71,500 |
| Aug 8, 25 | MARIANI PETER J | other | 90,000 |
| Aug 8, 25 | Kim Jiny | other | 22,000 |
| Aug 8, 25 | Capponi Vincent | other | 89,100 |
| Aug 8, 25 | Capponi Vincent | other | 111,100 |
Our CTSO Coverage
We haven't published any research on CTSO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CTSO Report →